State Street Corp Purchases 21,729 Shares of Enfusion, Inc. (NYSE:ENFN)

State Street Corp raised its position in Enfusion, Inc. (NYSE:ENFN) by 2.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 952,895 shares of the company’s stock after buying an additional 21,729 shares during the quarter. State Street Corp’s holdings in Enfusion were worth $9,043,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Arizona State Retirement System acquired a new position in Enfusion during the second quarter worth about $86,000. Harbor Capital Advisors Inc. grew its holdings in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the last quarter. Belvedere Trading LLC bought a new stake in shares of Enfusion during the 3rd quarter valued at approximately $114,000. Paloma Partners Management Co acquired a new position in Enfusion during the 3rd quarter worth approximately $157,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares during the last quarter. 81.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ENFN has been the topic of a number of research reports. Stifel Nicolaus boosted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Enfusion currently has an average rating of “Hold” and a consensus target price of $10.25.

Enfusion Stock Performance

ENFN stock opened at $10.69 on Friday. The business has a 50-day simple moving average of $9.80 and a two-hundred day simple moving average of $9.04. The company has a market capitalization of $1.37 billion, a P/E ratio of 267.32, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97. Enfusion, Inc. has a 52-week low of $7.52 and a 52-week high of $11.38.

Insider Activity at Enfusion

In related news, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 46,918 shares of company stock valued at $484,037. 36.44% of the stock is owned by insiders.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.